Aro Biotherapeutics
PrivateLast Round
Series B
Nov 28, 2023
Total Funding Raised
$142.5M
Company Overview
Aro Biotherapeutics is a biotechnology company that develops tissue-targeted genetic medicines using a proprietary protein platform called Centyrins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aro Biotherapeutics Comparables
Compare Aro Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Athebio AG | 83% | |
| Affibody AB | 83% | |
| Affilogic | 81% |
Aro Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 28, 2023 | ||||
| Series A | Jan 5, 2021 | ||||
| Seed | Dec 11, 2018 |
Key People
Founding team and executive leadership
Aro Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMotiv | Seed, Series A |
| Cowen Private Investments | Series A, Series B |
| Ridgeback Capital | Series A |
| TD Securities | Series A, Series B |
| Blue Owl Capital | Series A, Series B |
| Northpond Ventures | Series B, Series A |
| HealthCap | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 19, 2026
ABX1100, a targeted genetic therapy, is advancing in the rare disease pipeline.
- Jan 7, 2025
Glenn Crater, MD, appointed as new Chief Medical Officer.
Recent news
Latest coverage and updates
- is_developingOct 12, 2026
Aro Biotherapeutics Company is developing tissue-targeted short-interfering RNA (siRNA) medicines
- hiresSep 29, 2026
Aro Biotherapeutics Company appoints biotechnology executive Brett Blackman, Ph.D., to its Board of Directors in Pennsylvania on Sep 29th '26
Aro Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Aro Biotherapeutics's valuation, stock price, and market status.
Is Aro Biotherapeutics a public or private company?
Aro Biotherapeutics is a private company.
What is the current stock price of Aro Biotherapeutics?
Aro Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Aro Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aro Biotherapeutics worth (valuation)?
Valuation information for Aro Biotherapeutics is not publicly available.
Can I buy Aro Biotherapeutics stock?
Aro Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aro Biotherapeutics's last funding round?
Aro Biotherapeutics's most recent funding round was Series B on November 28, 2023.
Who are the main investors in Aro Biotherapeutics?
Key investors in Aro Biotherapeutics include Cowen Private Investments, TD Securities, Blue Owl Capital, Northpond Ventures, Anthelion Capital.
Will Aro Biotherapeutics IPO soon?
No public IPO plans have been announced for Aro Biotherapeutics.
How can I track Aro Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Aro Biotherapeutics's shares on secondary markets.